Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/99322
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Karlson, B. | - |
dc.contributor.author | Palmer, M. | - |
dc.contributor.author | Nicholls, S. | - |
dc.contributor.author | Lundman, P. | - |
dc.contributor.author | Barter, P. | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | European Journal of Preventive Cardiology, 2016; 23(7):744-747 | - |
dc.identifier.issn | 2047-4873 | - |
dc.identifier.issn | 2047-4881 | - |
dc.identifier.uri | http://hdl.handle.net/2440/99322 | - |
dc.description.abstract | Background: Achieving the greatest reduction in atherogenic lipoproteins requires the optimum dose and potency of statin. Using data from the VOYAGER meta-analysis, we determined doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). Methods: Least squares mean percentage change in LDL-C and non-HDL-C was calculated using 38,052 patient exposures to rosuvastatin 5-40 mg, atorvastatin 10-80 mg and simvastatin 10-80 mg. Equipotent doses were estimated by linear interpolation between actual adjacent doses.Results: Rosuvastatin 5 mg reduced LDL-C by 39% and non-HDL-C by 35%. Equivalent reductions in LDL-C required atorvastatin 15 mg or simvastatin 39 mg. Equivalent reductions in non-HDL-C required atorvastatin 14 mg or simvastatin 42 mg. Rosuvastatin 10 mg reduced LDL-C by 44% and non-HDL-C by 40%. Equivalent reductions in LDL-C required atorvastatin 29 mg or simvastatin 72 mg. Equivalent reductions in non-HDL-C required atorvastatin 27 mg or simvastatin 77 mg. Rosuvastatin 20 mg reduced LDL-C by 50% and non-HDL-C by 45%. Equivalent reductions in LDL-C and non-HDL-C required atorvastatin 70 mg and atorvastatin 62 mg, respectively, and were not achieved with the maximum 80 mg dose of simvastatin. Rosuvastatin 40 mg reduced LDL-C by 55% and non-HDL-C by 50%. Comparable reductions were not achieved with the maximum 80 mg doses of atorvastatin or simvastatin. Conclusions: Regarding reductions in LDL-C and non-HDL-C, each rosuvastatin dose is equivalent to doses 3-3.5 times higher for atorvastatin and 7-8 times higher for simvastatin. | - |
dc.description.statementofresponsibility | Björn W Karlson, Michael K Palmer, Stephen J Nicholls, Pia Lundman, Philip J Barter | - |
dc.language.iso | en | - |
dc.publisher | European Society of Cardiology | - |
dc.rights | © 2016 by European Society of Cardiology | - |
dc.source.uri | http://dx.doi.org/10.1177/2047487315598710 | - |
dc.subject | Rosuvastatin | - |
dc.subject | atorvastatin | - |
dc.subject | low-density lipoprotein cholesterol | - |
dc.subject | non-high-density lipoprotein cholesterol | - |
dc.subject | simvastatin | - |
dc.title | Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: results from the VOYAGER meta-analysis | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1177/2047487315598710 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Nicholls, S. [0000-0002-9668-4368] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.